Submitted by Anonymous (not verified) on 1 October 2026 - 14:26
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised
Source: